Evaluation on a supersaturatable self-microemulsifying (s-smdds) formulation of biphenyl dimethyl dicarboxylate (BDD) in Vitro and in Vivo

To enhance the dissolution and oral bioavailability of poorly water-soluble biphenyl dimethyl dicarboxylate (BDD), supersaturatable self-microemulsifying drug delivery system (S-SMEDDS) was developed by adding a polymer PVP to prevent precipitation maintain supersaturate state in vivo. Ternary phase diagrams were drawn evaluate microemulsification domain. The formulations characterized testing physical stability drug, particle size zeta potential. pharmacokinetic study beagle dogs performed for S-SMEDDS, SMEDDS formulation market drop pills. optimized S-SMEDDS consist 35% (w/w) Cremphor EL35, 33% Transcutol HP, 30% MCT 2% PVPK30 each excipient showed minimum mean droplet (37.71 ± 0.87nm) optimal release profile better water compared with absent SMEDDS. vivo studies that had significantly increased Cmax area under plasma concentration-time curve (AUC) (P < 0.01). should be an effective dosage form improving water-insoluble BDD.